Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 20 percent weight/volume - solutions producing osmotic diuresis; mannitol

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mannitol, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - osmitrol intravenous infusion (mannitol intravenous infusion, bp) can be used in: the promotion of diuresis in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; the reduction of intraocular pressure when the pressure cannot be lowered by other means; the reduction of intracranial pressure and treatment of cerebral oedema by reducing brain mass and; promoting the urinary excretion of toxic substances.

Kenya - English - Pharmacy and Poisons Board

medisel kenya ltd p.o box 540-01000, thika - mannitol bp - infusion - mannitol bp 20 gm - mannitol

Kenya - English - Pharmacy and Poisons Board

amanta healthcare limited c/o surgilinks ltd plot no. 876 national highway no. 8 hariyana- - mannitol intravenous infusion bp - infusion - 20gm/100ml - intravenous solutions: solutions producing

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

15%) infusion viaflo bags (baxter healthcare ltd - mannitol - infusion - 150mg/1ml

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 250 mg in 1 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

qatar pharma, qatar - mannitol - intravenous infusion - 10 %

Kenya - English - Pharmacy and Poisons Board

claris otsuka private limited survey no. 199 to 201 & 208 to 210, village - mannitol bp - solution for infusion - 20%wv - intravenous solutions: solutions producing

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 20 g in 100 ml - mannitol injection is indicated for: - reduction of intracranial pressure and treatment of cerebral edema. - reduction of elevated intraocular pressure. mannitol injection is contraindicated in patients with: - hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] -   active intracranial bleeding except during craniotomy. the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .  no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal

United States - English - NLM (National Library of Medicine)

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] . - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in resp